Publikationen in Zusammenarbeit mit Forschern von Catholic University of the Sacred Heart (14)

2024

  1. Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia

    Leukemia

2023

  1. Prediction of Nonrelapse Mortality in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation with Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis

    HemaSphere

2022

  1. Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia

    Bone Marrow Transplantation, Vol. 57, Núm. 11, pp. 1657-1663

  2. Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (Bone Marrow Transplantation, (2022), 57, 11, (1657-1663), 10.1038/s41409-022-01781-9)

    Bone Marrow Transplantation

  3. Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age

    American Journal of Hematology, Vol. 97, Núm. 8, pp. 1065-1074

  4. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 57, Núm. 4, pp. 562-571

2021

  1. Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia

    Transplantation and Cellular Therapy, Vol. 27, Núm. 2, pp. 171.e1-171.e8

  2. Outcome of T-cell–replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Cancer, Vol. 127, Núm. 14, pp. 2507-2514

  3. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

    Journal of Hematology and Oncology, Vol. 14, Núm. 1

2020

  1. Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia

    American Journal of Hematology, Vol. 95, Núm. 10, pp. 1200-1208

2018

  1. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

    British Journal of Haematology, Vol. 183, Núm. 3, pp. 411-420

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2013

  1. New autoimmune diseases after cord blood transplantation: A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation

    Blood, Vol. 121, Núm. 6, pp. 1059-1064

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051